Generic Risvan Availability
Last updated on Jun 12, 2024.
Risvan is a brand name of risperidone, approved by the FDA in the following formulation(s):
RISVAN (risperidone - for suspension, extended release;intramuscular)
Has a generic version of Risvan been approved?
No. There is currently no therapeutically equivalent version of Risvan available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Risvan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods for the preparation of injectable depot compositions
Patent 10,058,504
Issued: August 28, 2018
Inventor(s): Gutierro Aduriz Ibon & Gomez Ochoa Maria Teresa
Assignee(s): LABORATORIOS FARMACEUTICOS ROVI, S.A.Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Antipsychotic injectable depot composition
Patent 10,085,936
Issued: October 2, 2018
Inventor(s): Gutierro Aduriz Ibon & Gomez Ochoa Maria Teresa
Assignee(s): LABORATORIOS FARMACEUTICOS ROVI, S.A.The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Antipsychotic injectable depot composition
Patent 10,182,982
Issued: January 22, 2019
Inventor(s): Gutierro Aduriz Ibon & Gomez Ochoa Maria Teresa
Assignee(s): LABORATORIOS FARMACEUTICOS ROVI S.A.The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Methods for the preparation of injectable depot compositions
Patent 10,195,138
Issued: February 5, 2019
Inventor(s): Gutierro Aduriz Ibon & Gomez Ochoa Maria Teresa
Assignee(s): LABORATORIOS FARMACEUTICOS ROVI, S.A.Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Risperidone or paliperidone implant formulation
Patent 10,335,366
Issued: July 2, 2019
Inventor(s): Gutierro Aduriz Ibon & Franco Rodríguez Guillermo
Assignee(s): Laboratorios Farmacéuticos Rovi, S.A.The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Antipsychotic Injectable Depot Composition
Patent 10,463,607
Issued: November 5, 2019
Inventor(s): Gutierro Aduriz Ibon & Gomez Ochoa Maria Teresa
Assignee(s): LABORATORIOS FARMACEUTICS ROFI S.A.The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Methods for the preparation of injectable depot compositions
Patent 10,881,605
Issued: January 5, 2021
Inventor(s): Gutierro Aduriz Ibon & Gomez Ochoa Maria Teresa
Assignee(s): LABORATORIOS FARMACEUTICOS ROVI, S.A.Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Risperidone or paliperidone implant formulation
Patent 11,007,139
Issued: May 18, 2021
Inventor(s): Gutierro Aduriz Ibon & Franco Rodriguez Guillermo
Assignee(s): Laboratorios Farmacéuticos ROVI, S.A.The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Risperidone or paliperidone implant formulation
Patent 11,173,110
Issued: November 16, 2021
Inventor(s): Gutierro Aduriz Ibon & Franco Rodriguez Guillermo
Assignee(s): Laboratorios Farmacéuticos Rovi, S.A.The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Antipsychotic injectable depot composition
Patent 11,241,377
Issued: February 8, 2022
Inventor(s): Gutierro Aduriz Ibon & Gomez Ochoa Maria Teresa
Assignee(s): LABORATORIOS FARMACEUTICOS ROVI S.A.The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Patent 11,752,092
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Patent 11,752,093
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
-
Patent 11,759,416
Patent expiration dates:
- May 31, 2031✓
- May 31, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 29, 2027 - NEW PRODUCT
More about Risvan (risperidone)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: atypical antipsychotics
- Breastfeeding
Patient resources
Other brands
Risperdal, Uzedy, Risperdal Consta, Perseris, ... +2 more
Professional resources
Other brands
Risperdal, Uzedy, Risperdal Consta, Perseris, Rykindo
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.